BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06096090 (aldesleukin in Alzheimer's Disease): BVCT ex-ante prediction vs. reported outcome

On 24 Jul 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 29 Oct 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT06096090
Drug Name
aldesleukin
Drug MoA
low-dose recombinant IL2
Drug Modality
peptide
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Alzheimer's Disease
Human Patients
40
Sponsor
Coya Therapeutics
Phase
Phase 2

Prediction of , index 1696

Prospective Prediction
Prediction Index
1696
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in ADAS-Cog13 or CDR-SB)
Technical Prediction
FAILURE (statistically insignificant clinical benefit in ADAS-Cog13 or CDR-SB)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
97 days in advance
Readout Data Interpretation
aldesleukin failed to meet the exploratory efficacy endpoints ADAS-Cog14 or CDR-SOB
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease
Phase
Phase 2
Status
Unknown
Enrollment
40
Lead sponsor
The Methodist Hospital Research Institute
Conditions
Alzheimer Disease
Interventions
DRUG: Interleukin-2; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-01-01
Primary completion
2025-12-30
Completion
2025-12-30
Primary outcomes
  • To assess the safety and the tolerability of IL-2 in AD patients (6 months treatment phase)

NCT06096090 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials